Q-omics provides the consensus-scored IMPG1 profile across patient tissues and cancer cell-line models. IMPG1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, IMPG1 is differentially expressed in 13, with the highest sampling consensus in CHOL. Additionally, IMPG1 RNA expression shows 18,693 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, CHOL, and THYM as cancer lineages where IMPG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IMPG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IMPG1 survival associations across molecular data types. IMPG1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IMPG1 RNA expression–survival associations across cancer types. High IMPG1 expression shows unfavorable associations in CESC, MESO and UVM, but favorable associations in HNSC, READ and SCLC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for IMPG1 RNA expression.
This table summarizes IMPG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for IMPG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IMPG1 shows lower tumor expression in KIRC and higher tumor expression in CHOL, BLCA, STAD, COAD and LIHC. The CHOL box plot shows higher IMPG1 RNA expression in tumor versus normal tissue (log2 FC = +0.473, t-test p < 0.001).
This table shows molecular features associated with IMPG1 in patient tissues and cancer cell lines. In patient samples, IMPG1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IMPG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
